234,464 Shares in Insulet Corporation $PODD Acquired by Jupiter Asset Management Ltd.

Jupiter Asset Management Ltd. acquired a new position in Insulet Corporation (NASDAQ:PODD) in the fourth quarter, Holdings Channel reports. The fund acquired 234,464 shares of the medical instruments supplier’s stock, valued at approximately $66,644,000.

A number of other large investors also recently bought and sold shares of PODD. Larson Financial Group LLC raised its stake in Insulet by 114.6% in the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 47 shares in the last quarter. Elyxium Wealth LLC bought a new position in Insulet in the fourth quarter worth approximately $28,000. Measured Wealth Private Client Group LLC bought a new position in Insulet in the third quarter worth approximately $49,000. Osterweis Capital Management Inc. bought a new position in Insulet in the second quarter worth approximately $51,000. Finally, Zions Bancorporation National Association UT raised its stake in Insulet by 57.3% in the third quarter. Zions Bancorporation National Association UT now owns 173 shares of the medical instruments supplier’s stock worth $53,000 after buying an additional 63 shares in the last quarter.

More Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: William Blair initiated coverage on Insulet with an Outperform rating, arguing that the valuation gap is hard to justify, which adds another bullish analyst view on the name.
• Positive Sentiment: RBC reaffirmed its Outperform rating and kept a $280 price target, signaling confidence in Insulet’s longer-term growth potential.
• Positive Sentiment: Zacks highlighted continued momentum in Omnipod 5, pointing to the company’s Q1 beat, raised 2026 outlook, and expanding global rollout as key growth drivers.
• Neutral Sentiment: Insulet announced it will present at the William Blair 46th Annual Growth Stock Conference on June 3, which is a routine investor-relations update and could attract attention but is not a direct business catalyst. Article: Insulet to Participate in William Blair 46th Annual Growth Stock Conference
• Neutral Sentiment: Citigroup cut its price target on Insulet to $165 from $175 while maintaining a Neutral rating, reflecting a more cautious near-term view despite still implying upside from current levels.
• Neutral Sentiment: Zacks also noted a Hold rating with a $163 target, suggesting analysts see decent growth but limited near-term room for a stronger rerating.
• Negative Sentiment: A U.S. appeals court overturned Insulet’s $452 million trade-secret verdict against EOFlow, removing a potential legal win and likely weighing on sentiment around the company’s competitive and litigation outlook. Article: US court overturns Insulet’s $452 mln insulin-pump trade secret verdict against EOFlow

Insulet Price Performance

NASDAQ PODD opened at $142.65 on Friday. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81. The stock’s fifty day moving average price is $185.26 and its 200 day moving average price is $246.01. Insulet Corporation has a 1 year low of $140.63 and a 1 year high of $354.88. The company has a market cap of $9.88 billion, a price-to-earnings ratio of 33.17, a PEG ratio of 1.15 and a beta of 1.20.

Insulet (NASDAQ:PODD) last released its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The firm had revenue of $761.70 million for the quarter, compared to the consensus estimate of $729.89 million. During the same period in the prior year, the firm earned $1.02 EPS. The firm’s revenue was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, equities research analysts forecast that Insulet Corporation will post 6.43 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. JPMorgan Chase & Co. reduced their price target on Insulet from $340.00 to $275.00 and set an “overweight” rating on the stock in a research report on Thursday, May 7th. William Blair began coverage on Insulet in a research report on Wednesday, May 20th. They set an “outperform” rating on the stock. Sanford C. Bernstein lowered their price target on Insulet from $330.00 to $200.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Royal Bank Of Canada reissued an “outperform” rating and issued a $280.00 price target on shares of Insulet in a report on Wednesday. Finally, Oppenheimer lowered their price target on Insulet from $300.00 to $210.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Twenty-one analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $252.04.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.